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Guidelines for the prevention and treatment of venous thromboembolism (VTE) are aimed to improve patients’ 
safety and quality of life by appropriate prophylaxis and treatment of deep venous thrombosis (DVT) and pulmonary 
embolism (PE).
These guidelines relate to adult cancer patients treated non-surgically. Recommendations included in those guidelines 
do not relate to paediatric patients.
The guidelines presented here directed to physicians and other healthcare professionals taking care of mentioned 
patients: clinical oncologists, haematologists, radiotherapists, pulmonologists, oncological gynaecologists, internal 
medicine physicians, and GPs.
•	  Venous thromboembolism (VTE) comprises a serious problem in oncology because it is the most common compli-
cation as well as the second most common cause of cancer-related deaths. 
•	  the term “venous thromboembolism” includes the cases of DVT and PE; however, the former is a primary event and 
the latter is a secondary result.
•	  Active malignant disease classifies patients to a group with at least moderate risk of VTE.
•	  D-dimer levels could be increased in cancer patients without concomitant VTE. 
•	  D-dimer levels below cut-off value (negative D-dimer) do not exclude VTE in cancer patients. 
•	  In patients with active malignant disease with clinical symptoms suggesting VTE ultrasound (US) examination of 
deep veins or computed tomography angiography (angio-CT) should be performed, depending on the symptoms.
•	  Low-molecular-weight heparins (LMWH) are the drugs of choice in prevention and treatment of VTE in cancer 
patients. 
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•	  Antithrombotic treatment in cancer patients with DVT does not differ from treatment of cancer patients with PE, 
except clear indications to thrombolytic therapy. 
•	  Cancer patients with clinical symptoms suggesting PE (dyspnoea, chest pain or tachycardia) are per definition 
classified into the group of moderate or high clinical probability of PE.
•	  The majority of PE cases account for embolism, which do not warrant thrombolytic treatment and should be treated 
with LMWH, UFH, or fondaparinux; LMWHs are the treatment of choice in cancer patients with VTE.
•	  Cancer patients have increased risk of recurrence of VTE.
•	  Available evidence does not justify the use of antithrombotic drugs to prolong survival in cancer patients.
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Abbreviations, explanations, and terminology used in this publication (in alphabetical order)
Angio-CT — computed tomography angiography
Angio-MR — magnetic resonance angiography
Anti-Xa — (activity) inhibiting factor Xa
APTT — activated partial thromboplastin time
ASA — acetylsalicylic acid
ASD — atrial septal defect
BMI — body mass index
b.w. — body weight
CR — complete remission
CRP — C-reactive protein
CT — computed tomography
CVI — chronic venous insufficiency
DOAC — direct oral anticoagulants
DVT — deep venous thrombosis
eGFR — estimated glomerular filtration rate
ESA — erythropoiesis stimulating agents
HITT — heparin-induced thrombocytopenia
i.m. — intramuscular 
INR — international normalised ratio
IU — international unit
IV — intravenously
LMWH — low-molecular-weight heparin
MR — magnetic resonance
OS — overall survival
PE — pulmonary embolism
PESU — graduated compression stockings
PFS — progression free survival
PT — prothrombin time
PTS — post-thrombotic syndrome
PUP — intermittent pneumatic pressure device
RT — radiotherapy 
r-tPA — recombinant tissue plasminogen activators
s.c. — subcutaneously
SK — streptokinase
SVCS — superior vena cava syndrome
US — ultrasound
UFH — unfractionated heparin
VEGF — vascular endothelial growth factor
VKA — vitamin K antagonists
VSD — ventricular septal defect
VTE — venous thromboembolism
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General part
1. Introduction
Venous thromboembolism (VTE) comprises a serious 
problem in oncology because it is the most common com-
plication as well as the second most common cause of can-
cer-related deaths [1–5]. The risk of VTE is 4–6-fold higher in 
cancer patients as compare to the general population [1–5]. 
Population-based trials revealed that year-year cumulative 
incidence of VTE is between 0.8–8% [5]. Moreover, VTE is 
4–13-fold more frequent in patients with advanced cancer 
compared to the patients with early stage cancers [5]. It 
mainly affects patients with brain malignant tumours, pan-
creatic, lung, gastric, endometrial, bladder, and renal cancers 
[5]. Clinical symptoms of VTE are noted in approximately 
30% of pancreatic and lung cancer patients [3, 4]. Of note, 
in cancer patients with VTE the risk of recurrent deep venous 
thrombosis (DVT) and/or pulmonary embolism (PE) is three-
fold higher than in non-cancer patients with VTE [6, 7]. VTE 
recurrence risk is highest during the first few months after 
cancer diagnosis and can continue for many years after the 
first thrombosis episode [5]. During chemotherapy the risk 
of VTE is increased several times as compared with non-can-
cer individuals, especially in patients with pancreatic and 
gastric cancer [5, 8].
It should be added that VTE itself, antithrombotic treat-
ment, as well as VTE complications adversely affect the qual-
ity of life of cancer patients. Additionally, the risk of death 
in cancer patients with VTE is higher than in those without 
such a complication, which results from higher cancer ag-
gressiveness and interaction of cancer with haemostasis 
components [7, 9]. It was also noticed that in patients with 
pancreatic cancer treated with chemotherapy occurrence 
of clinically overt VTE was associated with worsening of 
responses and shortening of progression-free survival (PFS) 
and overall survival (OS) [7]. In the group of cancer pa-
tients with VTE deaths are eight-fold more frequent than 
in patients with VTE during other underlying diseases [7]. 
It should be also highlighted that the risk of VTE in cancer 
patients increases as more co-morbidities occur [3, 4].
Despite the common prevalence of VTE and its unfa-
vourable influence on prognosis in cancer patients treat-
ed non-surgically, this problem is still underestimated by 
treating physicians [10, 11]. Thereby, inappropriate pre-
vention and treatment could be a consequence. There are 
an increasing number of patients with cancer-related VTE, 
possibly due to higher mean age of patients, longer OS 
resulting from progress of anticancer treatment, as well as 
better diagnostic procedures [12]. These are the reasons for 
Polish experts’ and scientific societies’ initiative to develop 
guidelines to help physicians to identify cancer patients 
with increased VTE risk in daily clinical practice, and to 
use optimal prevention and appropriate treatment of VTE 
as needed. For this purpose, available medical literature 
from the last 20 years was analysed, including published 
international and Polish guidelines regarding this topic:
 — ISTH (International Society on Thrombosis and Haemo-
stasis) [13, 14];
 — ASCO (American Society of Clinical Oncology) [8, 15–17];
 — ESMO (European Society for Medical Oncology) [18];
 — NCCN (National Comprehensive Cancer Network) [19, 
20];
 — ACCP (American College of Chest Physicians) [21, 22];
 — Polish guidelines [23–25];
 — AIOM (Italian Association of Medical Oncology) [26];
 — French National Guidelines [27] and French National 
Federation of Cancer Centres [28];
 — ESC (European Society of Cardiology) [29];
 — International Consensus Statement [30].
The abovementioned guidelines use a grading of 
strength and reliability of evidence associated to a particular 
topic based on the GRADE (Grading of Reco mmendations 
Assessment Development and Evaluation Scale) system 
and ACCP guidelines published in 2012 and 2016 [31–33]. 
Guidelines were assessed as either strong [1] or weak [2]. 
The quality of data from published studies using EBM (evi-
dence-based medicine) rules, being a basis for guidelines, 
were described and marked with a letter (A), (B), or (C). 
Guidelines marked with letter (A) are manly based on ran-
domised clinical trials (RCT) with unambiguous results, and 
further studies probably will not elicit any changes. The let-
ter (B) indicates that further studies could possibly influence 
the changes of guidelines, whilst the letter (C) indicates low 
quality of available data, resulting mainly from scarce RCT, 
so further studies are very likely to change the guidelines. 
They are three levels of recommendation importance dis-
tinguished in the presented guidelines: 
 — 1A — strong recommendation, high-quality evidence;
 — 1B — strong recommendation, moderate-quality ev-
idence; 
 — 1C — strong recommendation, low- or very low-quality 
evidence;
 — 2A — weak recommendation, high-quality evidence;
 — 2B — weak recommendation, moderate-quality evi-
dence; 
 — 2C — weak recommendation, low- or very low-quality 
evidence.
Guidelines without brackets (with very few publications 
of low reliability, including ambiguous expert opinions) were 
considered by experts and scientific societies as currently 
suggested clinical management. Recommendations based 
on current literature could differ from current summaries of 
product characteristics.
2. Venous thromboembolism (VTE)
The term “venous thromboembolism” includes the cases 
of DVT and PE; however, the former is a primary event and 
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the latter is a secondary result. In approximately half of pa-
tients DVT is asymptomatic. In half of patients with DVT of 
the proximal part, asymptomatic (clinically silent) PE could 
be diagnosed. In many patients PE leading to death is the 
very first and only sign of VTE [34].
2.1. Complications of VTE 
Acute complications of DVT could cause PE, and in pa-
tients with ventricular septal defect (VSD) or atrial septal 
defect (ASD) even stroke or peripheral embolism.
Post-thrombotic syndrome (PTS) is a chronic compli-
cation of DVT, occurring in 20–50% of patients with DVT, 
often leading to chronic venous insufficiency (CVI), which 
manifests as pain of extremities, skin discoloration, and 
varicosities, and in the most advanced cases with hard-to-
heal ulcerations.
The outcome of acute PE can be fatal in 2–8% of patients. 
In 2–4% of patients, high risk or recurrent PE could lead 
to development of chronic thromboembolic pulmonary 
hypertension, which manifests as right ventricular heart 
failure, dyspnoea, oedema of lower extremities, and im-
paired exercise tolerance. This complication is associated 
with poor prognosis. 
Chronic complications of VTE are an important clinical 
problem due to their incidence and high cost of diagnos-
tic and therapeutic procedures. Additionally, in advanced 
stages they cause long-term inability to work and decreased 
quality of life [34].
2.2. Diagnosis of VTE
The patient’s physical examination should consider risk 
factors (subunit 3.1), symptoms related to location of disease 
(subunit 3.4), and in the case of suspicious of PE — previous 
or recent episodes of DVT.
Active malignant disease classifies patients to a group 
with at least moderate risk of VTE. Thus, cancer patients with 
clinical symptoms of VTE warrant immediate diagnostic 
tests, e.g. ultrasound (US) examination of deep veins in case 
of DVT symptoms and computed tomography angiography 
(angio-CT) of pulmonary arteries and US of deep veins in 
case of PE suspicious [34].
2.3. Prevention of VTE
Occurrence of VTE in cancer patient worsens the pro-
gnosis and decreases health-related quality of life [35]. 
Appropriate antithrombotic prevention used in cancer 
patients with high risk of VTE in non-surgical departments 
and in some outpatient patients could decrease the inci-
dence of VTE and thereby mortality due to PE [6, 36–38]. 
2.4. Treatment of cancer patients with VTE
Antithrombotic treatment of cancer patients with VTE 
is divided into three phases (Figure 1):
 — initial treatment — 7–10 days;
 — long-term treatment — up to 3–6 months; 
 — chronic treatment — after 3–6 months [23]. 
Pulmonary embolism is divided into three categories: 
low, moderate and high risk or (much simplified) into cate-
gories that warrant (high risk) or do not warrant thrombo-
lytic treatment.
2.5. Antithrombotic drugs in prevention  
and treatment of patients with VTE 
2.5.1. Low-molecular-weight heparin (LMWH) administered 
subcutaneously (s.c.)
Dosing of LMWH in prevention of VTE:
 — dalteparin 5000 IU every 24 hours;
 — enoxaparin 40 mg every 24 hours;
 — nadroparin 3800 IU every 24 hours, in patients of body 
weight over 70 kg 5700 IU every 24 hours [39].
Dosing of LMWH during initial treatment of VTE (in al-
phabetical order): 
 — dalteparin (100 IU/kg every 12 hours or 200 IU/kg every 
24 hours) — during initial treatment dosing every 12 
hours is preferred;
 — enoxaparin (1 mg/kg every 12 hours or forte form 1.5 
mg/kg every 24 hours);
 — nadroparin (86 IU/kg = 0.1 ml/kg b.w. every 12 hours or 
171 IU/kg b.w. = 0.1 ml/kg every 24 hours) [39].
2.5.2. Unfractionated heparin (UFH)
Dosing of UFH in prevention of VTE:
 — 5000 IU every 8 hours IV or s.c.
 — Dosing of UFH during initial treatment of VTE:
 — initial dose of UFH (bolus) could be administered IV and 
should be adjusted to body weight and amount to 80 
IU/kg b.w. (although not lower than 5000 IU), then — 
IV with APTT monitoring (during continuous infusion 
APTT should be prolonged 1.5–2.5-fold as compare to 
control, which reflects a drug serum concentration of 
0.3–0.6 IU of anti-Xa activity);
 — the infusion rate is based on body weight and amounts 
to 18 IU UFH/kg b.w./hour, provided that it is not lower 
than 1250 IU/hour; 
 — UFH could be also administered s.c.; in those cases UFH 
is initially administered IV in the dose of 5000 IU in bo-
Figure 1. Phases of antithrombotic treatment of cancer patients with 
venous thromboembolism
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lus and then s.c. 17500 IU every 12 hours with APTT 
monitoring;
 — during establishing of UFH dose Reschke normograms 
could be helpful [40];
 — although the risk of heparin-induced thrombocytopae-
nia (HITT) during treatment with UFH is low, from the 
4th to 14th day of UFH therapy or to UFH therapy termi-
nation, platelets count should be assessed every 2–3 
days. Patients previously treated with heparin could 
warrant earlier assessment of platelet count as well as 
more frequent monitoring of this parameter considering 
the possibility of earlier occurred HITT;
 — UFH should be administered for 5–7 days, and in justified 
cases therapy should be prolonged to 10 days. 
2.5.3. Fondaparinux 
Dosing of fondaparinux in prevention of VTE:
2.5 mg every 24 hours s.c.
Dosing of fondaparinux in the treatment of VTE:
every 24 hours s.c. in doses:
•	 in patients with body weight below 50 kg — 5 mg;
•	 in patients with body weight between 50–100 kg 
— 7.5 mg;
•	 in patients with body weight over 100 kg — 10 mg.
2.5.4. Vitamin K antagonists (VKA) (acenocoumarol  
and warfarin) 
VKA are used orally with monitoring of prothrombin 
time (PT) converted into the INR value (INR value should 
be in the range between 2.0–3.0; in patients with higher 
bleeding risk INR should be about 2.0).
In patients taking VKA in stable dose (after its establish-
ment) it is suggested to measure INR not less frequently 
than every four weeks. In patients taking VKA in stable dose 
with INR values significantly varying, more frequent INR 
assessment is suggested — every 1–2 weeks [2C]. Patients 
should receive dietary counselling about vitamin K levels 
in food products and possible drug-drug interactions, es-
pecially with over-the-counter (OTC) drugs. For stability of 
vitamin K treatment a balanced diet is needed with similar 
daily dose of vitamin K.
2.5.5. Direct oral anticoagulants (DOAC)
Currently they are not recommended in cancer patients 
with VTE. LMWH is a drug of choice in cancer patients using 
DOAC for other indications, e.g. cardiological, especially atri-
al fibrillation, and those who experienced VTE, because such 
incidence suggests failure of anticoagulation. LMWHs are 
not recommended in chronic stroke prevention in patients 
with atrial fibrillation.
 — Oral direct thrombin inhibitors:
•	 dabigatran.
 — Oral direct inhibitors of factor Xa:
•	 rivaroxaban, apixaban, edoxaban.
2.6. Contradictions to pharmacological 
antithrombotic treatment
Contraindications to antithrombotic treatment should 
be considered in each case of decision making about the 
use of those drugs in cancer patients.
Absolute contraindications include the following:
 — clinically important haemorrhagic diathesis;
 — active bleeding;
 — dissecting aortic aneurysm;
 — haemorrhagic stroke (two weeks to three months from 
incidence, depending on thromboembolic risk); 
 — hypertensive crisis;
 — infective endocarditis;
 — HITT — only related to UFH and LMWH.
 — Relative contraindications include the following:
 — active peptic ulcer disease;
 — primary or metastatic neoplasm of central nervous sys-
tem;
 — severe hepatic insufficiency with tendency to bleed. 
IMPROVE scale facilitates assessment of bleeding risk 
(Table I) [41].
2.7. Non-pharmacological methods for 
antithrombotic prevention
During use of pharmacological antithrombotic preven-
tion in patients immobilised due to acute disease it is recom-
mended to concomitantly use mechanical prevention methods 
with graduated compression stockings (PESU) or intermittent 
Table I. Point scale for bleeding risk assessment in hospitalised, acutely 
ill patients with no need for surgical intervention, with own modification 
(so called IMPROVE scale) [41] 
Bleeding risk factor Number of 
points
eGFR ≥ 60 ml/min/m2 1
Male gender 1
Age 40–84 years 1
Malignant disease 2
Rheumatic disease 2
Central vein catheter 2
Hospitalisation in intensive care unit or 
cardiological intensive care unit
2.5
eGFR < 30 ml/min/m2 2.5
Hepatic insufficiency (INR > 1.5) 2.5
Age ≥ 85 years 3.5
Platelets count < 50 G/l 4
Bleeding during last three months before 
hospitalisation
4
Active gastric and duodenal peptic ulcer disease 4.5
High bleeding risk > 7
eGFR — estimated glomerular filtration rate; INR — international normalised ratio
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pneumatic pressure devices (PUP). Mechanical prevention is 
also recommended in the case of contraindication to pharma-
cological antithrombotic prevention.
2.8. Thrombolytic drugs 
Dosing in systemic administration during treatment of 
patients with PE:
 — alteplase (rt-PA):
•	 standard scheme: 100 mg IV during two hours;
•	 accelerated scheme (rarely used): 0.6 mg/kg b.w. (max. 
50 mg) during 15 minutes;
 — streptokinase (SK):
•	 accelerated scheme (preferreda): 1.5 mln IU IV during 
2 hours;
•	 standard scheme: 250,000 IU IV during 30 minutes, 
then 100,000 IU/hour during 12–24 hours;
 — urokinase: 
•	 accelerated scheme: 3 mln IU IV during two hours.
•	 standard scheme: 4400 IU/kg IV during 10 minutes, 
then 4400 IU/hour during 12–24 hours.
Dosing during administration to implantable port sys-
tem: 
 — rt-PA IV in the dose of 0.9 mg/kg b.w. (max. 90 mg):
•	 10% of calculated dose in bolus during 2 minutes;
•	 remaining 90% of dose IV during 60 minutes.
2.9. Contradictions to thrombolytic drugs 
according to 2014 European Society of Cardiology 
guidelines [29]
Absolute contraindications include the following:
 — active bleeding to internal organs;
 — dissecting aortic aneurysm;
 — haemorrhagic stroke; 
 — cerebrovascular diseases (aneurysms, arteriovenous 
fistula, vascular malformations);
 — tumours of central nervous system;
 — ischaemic stroke within last six months;
 — head trauma or multiple organ injury or surgery within 
last three weeks. 
 — Relative contraindications include the following:
 — episode of transient ischaemic attack within last six 
months;
 — bleeding in the gastrointestinal or urinary tract;
 — resuscitation procedures leading to organs injury;
 — hypertension with values exceeding 200/120 mm Hg;
 — severe hepatic insufficiency;
 — bacterial endocarditis;
 — pregnancy or first week after giving birth;
 — active peptic ulcer disease;
 — status after biopsy of an organ not susceptible to pres-
sure.
Detailed part
3. Risk factors, symptoms, forms,  
and diagnosis of VTE
3.1. Patient-related risk factors of VTE
The same as in population of non-cancer patients [23, 42]:
age > 40 years (increased risk with age);
 — obesity (BMI > 30 kg/m2);
 — positive family history of VTE;
 — injuries (especially multiple organs or fracture of the 
bones of pelvis, proximal part of the femur, and other 
long bones of lower extremities);
 — stroke;
 — paresis of lower extremities, long-term immobilisation;
 — previous VTE;
 — congenital acquired thrombophilia;
 — sepsis; 
 — bedridden patient treated conservatively (e.g. due to 
severe pneumonia);
 — heart failure of III and IV NYHA class;
 — respiratory failure;
 — autoimmune diseases;
 — nephrotic syndrome;
 — paroxysmal nocturnal haemoglobinuria;
 — pressure on vein (e.g. mass, haematoma, arterial mal-
formation);
 — pregnancy and childbed;
 — long-term immobility due to advanced cancer, travelling 
(e.g. flight);
 — varicose veins of lower extremities;
 — acute infection.
3.2. Cancer-related risk factors of VTE
 — localization of the cancer (mainly pancreatic, gastric, 
lung, kidney, ovary cancer, and brain malignant tu-
mours); 
 — histopathology of cancer (VTE is most common in ad-
enocarcinomas);
 — cancer clinical stage;
 — increased D-dimer levels exceeding two-fold cut-off 
value could suggest increased risk of VTE [42]. It should 
be also underlined that isolated (e.g. with no relation 
with the clinical presentation) increased D-dimer level 
is never an indication to initiation of antithrombotic 
drug administration; 
 — the highest incidence of VTE is observed within the first 
3–6 months after diagnosis of cancer. 
3.3. Treatment-related risk factors of VTE
 — previous surgical operations, including anaesthesia;
 — chemotherapy or hormone therapy;
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 — antiangiogenic treatment;
 — radiotherapy;
 — transfusion of red cell concentrates;
 — erythropoiesis stimulating agents (ESA); 
 — corticosteroids;
 — central catheters [3, 4, 8].
3.3.1. Chemotherapy
Chemotherapy increases the risk through several 
mechanisms, including impairment and/or activation of 
vascular endothelial cells, decreased level of natural co-
agulation inhibitors, and platelets activation [3, 4, 43]. The 
results of prospective RCTs showed a significant decrease 
in VTE incidence in outpatients undergoing chemotherapy, 
receiving pharmacological antithrombotic prevention, as 
compare to patients without prevention [44–47]. Patients 
with pancreatic and lung cancer especially benefit from 
such prophylaxis [45, 47–56]. Patients who underwent 
systemic therapy in clinical settings differed significantly 
from patients recruited to clinical trials, as they have worse 
performance status, more advanced age, and more concom-
itant diseases, thus they are more likely to develop either 
VTE or bleedings. The type of cancer and its clinical stage, 
modality of systemic therapy and its duration, combination 
of systemic therapy with irradiation and supportive care, 
response to anticancer therapy (e.g. tumour lysis syndrome), 
patient’s nutritional status, hepatic and renal function, pa-
tient’s mobility, and vascular stasis all definitely influence 
the risk of VTE in cancer patients.
3.3.2. Hormone therapy
Monotherapy with tamoxifen is associated with a 2–3% 
risk of VTE, and this risk increases with patient’s age; breast 
cancer postmenopausal women are three-fold more like-
ly to develop VTE than patients before menopause. Aro-
matase inhibitors are associated with VTE less frequently 
than tamoxifen; however, the risk of VTE is significantly 
higher than in the healthy female population who did not 
undergo such therapy [3, 4].
In patients with pancreatic cancer during hormone ther-
apy the risk of DVT and PE significantly increases as com-
pared to such patients without hormone therapy. The risk 
of VTE is extremely high during therapy with GnRH agonists 
and oral antiandrogens, and longer hormone therapy dura-
tion in men is associated with more frequent VTE [57, 58].
3.3.3. Anti-angiogenic treatment
The prevalence of VTE is estimated to amount to 
several to several dozen per cent, depending on which 
anti-angiogenic drug is used (e.g. bevacizumab, thalid-
omide, lenalidomide, pomalidomide, gefitinib) [58–65]. 
The results of meta-analysis indicate the increased relative 
risk of VTE after treatment with bevacizumab (monoclo-
nal antibody against vascular endothelial growth factor 
[VEGF]) [59]. The general prevalence of VTE in this group 
of patients is 10.9% [60]. However, in patients with mul-
tiple myeloma the highest prevalence of VTE (34%) was 
noted during treatment with thalidomide in combination 
with doxorubicin, as well as in patients receiving lena-
lidomide together with high doses of dexamethasone 
due to recurrent disease [61]. It should be underlined 
that procoagulant effect of anti-angiogenic treatment 
increases through combination with cytotoxic drugs or 
corticosteroids.
Venous thromboembolism risk factors in myeloma pa-
tients include:
 — patient-related factors: older age, obesity, sedentary life-
style, immobilisation, past episode of VTE, and genetic 
predisposition to VTE;
 — disease-related factors: renal insufficiency, abnormali-
ties in chromosome 11, increased CRP level, and short-
chain disease;
 — treatment-related factors: immunomodulatory drugs 
(thalidomide, lenalidomide, pomalidomide) used alone 
or in combination with cytotoxic drugs [62].
The majority of VTE episodes in patients with multi-
ple myeloma are diagnosed during the initial treatment 
period [62].
3.3.4. Radiotherapy
Radiotherapy increases the risk of thrombosis through 
release of procoagulants and cytokines from cancer cells 
and directly through impairment of vascular vessels, 
thereby causing activation of vascular endothelial cells, 
leucocytes, and platelets; this increases also aggregation 
potential of these latter [63]. Additionally, radiothera-
py leads to loss of natural vascular resistance against 
thrombus formation. Moreover, acute radiation reaction 
after radiotherapy favours infections, which additionally 
potentiate procoagulant status. 
There is lack of large RTCs, documenting the incidence 
of VTE in patients who have undergone radiotherapy on dif-
ferent body areas due to a wide range of cancers. However, it 
was noted that in patients with Hodgkin’s lymphoma irradi-
ated on the area of mediastinal lymph nodes and in patients 
with left breast cancer during adjuvant radiotherapy the risk 
of cardiovascular complications is 2–7-fold higher as com-
pare to patients without irradiation of that area. The risk of 
the mentioned complications increases when the radiation 
dose administered on anterior heart surface exceeds 35–40 
Gy [63]. However, it should also be underlined that contem-
porary treatment of cancer patients is based on combination 
therapy, and a large proportion of those patients receive 
radiotherapy in combination with chemotherapy or tar-
geted therapies. For example, radiotherapy in patients with 
endometrial or cervical cancer is associated with approx. 
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5–7% risk of VTE, whilst radiotherapy in combination with 
cisplatin increases the risk of VTE in this group of patients 
up to 8.5–16.7% [63]. Venous thromboembolism was also 
reported after combination therapy (radiotherapy, chemo-
therapy, and/or targeted therapy) in patients with gastric, 
oesophageal, head-and-neck cancers as well as malignant 
brain tumours. Radiotherapy on the chest area in patients 
with indwelling central venous catheter is an independent 
risk factor of VTE occurring in upper extremities (OR 7.01; 
95% CI 1.42–34.66) [literature review in 63].
The patients underwent palliative radiotherapy quite 
frequently are characterised by limited mobility or even 
immobilisation, which could be the cause of approx. 15% 
of VTE cases. Use of high fractionated doses in patients 
during palliative radiotherapy could lead to tumour lysis 
syndrome and releasing procoagulants and cytokines from 
cancer cells, increasing risk of VTE. Moreover, those patients 
often enough receive supportive care, which additionally 
increases the risk of VTE (e.g. cancer-related cachexia treat-
ment — megestrol). In patients undergoing palliative radio-
therapy the bleeding risk could be even higher considering 
the large tumour volume, often infiltrating vascular walls of 
different calibre blood vessels, as well as the possibility of 
hypoproteinaemia and hepatic and renal dysfunctions in 
advanced cancer stages.
3.4. Symptoms and forms of VTE
3.4.1. Lower extremities VTE
The symptoms of lower extremities VTE could include: 
increased extremity girth, oedema, erythema, or calf ten-
derness lower extremity.
3.4.2. Upper extremities VTE
Deep venous thrombosis in upper extremities could 
cause different symptoms, including oedema, erythema, 
and excessive warmth as well as pain and paraesthesia 
of upper extremities, pain in shoulder, axilla, lower jaw, 
head and neck, and visible enlargement of veins in collat-
eral circulation in the area of the shoulder joint and chest. 
Symptoms of superior vena cava syndrome (SVCS) could be 
also detected. Difficulties in obtaining blood samples from 
central catheter or in IV fluids infusion through the catheter 
suggests thrombosis of the end of the catheter. 
3.4.3. Pulmonary embolism (PE)
Symptoms of PE are very different and depend on em-
bolism extent and the patient’s general condition. The most 
common symptoms of PE include: tachycardia (80% of pa-
tients), tachypnoea, dyspnoea (50% of patients), pleural pain 
(40% of patients), cough (25% of patients), and more rarely 
(< 10% of patients) the following: increased body tempera-
ture, haemoptysis, collapse, or fainting. 80% of patients with 
PE also have the symptoms of DVT. 
3.4.4. Migratory thrombophlebitis (Trousseau syndrome)
It affects only superficial veins, most frequently of atyp-
ical location (e.g. veins of upper extremities, chest), and is 
characterised by spontaneous regressions and recurrences. 
This entity is not included into the term of VTE, but this is 
a rare but characteristic syndrome of coagulation disorders 
in cancer patients. Resistance against antithrombotic treat-
ment is commonly observed.
3.4.5. Marantic endocarditis
Physical examination reveals new-onset heart murmurs 
and symptoms of disseminated embolism in cerebral, cor-
onary, splenic, renal and limbs arteries. Very often the first 
symptom of this disease is ischemic stroke with no new 
heart murmurs.
3.4.6. Hepatic vein thrombosis (Budd-Chiari syndrome)
The symptoms of this form of VTE include: abdomen 
discomfort, presence of ascites, hepatomegaly, and ab-
dominal pain. 
3.4.7. Thrombosis in the portal vein, splenic vein, mesenteric 
vein, and the renal veins
These are quite frequent forms of VTE in patients with 
non-proliferative cancers and in patients with primary he-
patic, pancreatic, kidney, and suprarenal cancers. Clinical 
symptoms include: abdominal pain, splenomegaly, oesoph-
ageal varices, and ascites.
3.4.8. Incidental VTE
An asymptomatic course of DVT and/or PE is relatively 
common in cancer patients [63]. Thrombus in pulmonary 
artery is accidentally detected in approx. 3% of patients, 
in which angio-CT is performed due to indications other 
than suspicion of PE. Cancer patients are considered to be 
especially exposed to incidental VTE localised in the abdo-
men [64–68]. It affects 2–5% of patients in which abdomen 
CT is performed. 
Symptoms of VDT and PE are not characteristic, and in 
many cases they raise no concerns among patients as well 
as clinicians. Deep venous thrombosis symptoms could also 
be attributable to cancer but not to new pathology [68, 69]. 
It is worth pointing out that VTE is observed in cancer 
patients regardless of whether the DVT and/or PE episode 
was symptomatic or asymptomatic [70]. 
3.5. Diagnosis 
Diagnosis of VTE in cancer patients differs from the di-
agnostic rules accepted for remaining patients with VTE 
[71–75]. In the majority of cancer patients D-dimer levels 
could be increased without simultaneous VTE. However, a 
D-dimer level below the cut-off value (“negative D-dimer”) 
does not exclude VTE in cancer patients. 
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VTE diagnosis should include US examination of deep 
veins, which ensures sensitivity and specificity of about 
93–100% related to proximal VTE and over 70% in the case 
of the calf VTE using following techniques [34]:
 — compression test in B presentation;
 — pulse Doppler method;
 — colour Doppler sonography;
 — duplex Doppler technique. 
Palaeography and angio-CT of venous vessels or mag-
netic resonance angiography (angio-MR) (mainly in suspi-
cions of DVT of iliac veins and thrombosis of superior and 
inferior vena cava — in borderline cases or proximal DVT 
of lower extremities) are less frequently performed [23].
Diagnosis of PE in cancer patients is based on angio-CT 
of pulmonary arteries, or less frequently on ventilation-per-
fusion scintigraphy [73].
Guidelines:
1. In the case of occurrence of PE and/or DVT clinical symp-
toms, diagnostic tests should be immediately performed 
— US of deep veins in the case of DVT symptoms and 
angio-CT of pulmonary arteries in suspicion of PE. 
2. In cancer patients with clinical symptoms of DVT and/
or PE antithrombotic treatment should be immediately 
initiated while waiting for results of diagnostic imaging 
tests [2C].
3.6. Searching for cancer in patients with VTE  
or PE — occult malignancy
The symptoms of VTE could precede the diagnosis of 
malignant disease [76, 77]. In up to 10% of patients can-
cer is diagnosed within several to several dozen months 
(most commonly during the first six months) from idiopathic 
thrombosis episode — so-called occult malignancy. The 
most frequent are prostate and colon cancers and more 
rarely lung, pancreatic, gastric, and bladder cancers [78]. Re-
cently identified risk factors of occult malignancy in patients 
after first VTE episode include: age > 60 years, current smok-
ing, and previous VTE episode due to transient factor [79].
The SOMIT study indicated that intensive screening 
diagnosis towards cancer in patients with VTE episode in-
creases the rate of malignant disease diagnosed in early 
stages, but is not associated with prolonged OS as com-
pare to patients who have undergone routine assessment 
towards cancer disease [80]. 
Published in 2015, a Canadian randomised study did not 
reveal significant differences in the rate of cancer diagnosis in 
patients with idiopathic VTE, who had undergone standard 
diagnostic evaluation towards cancers with consideration of 
gender and age, medical history, morphology and biochem-
ical blood tests, chest X-ray, in women: mammography and 
cytology exam, and in men: PSA level and prostate palpation, 
as compared to individuals in which standard evaluation was 
extended by abdominal and pelvic CT, virtual colonoscopy, 
and gastroscopy. In the first group, cancers were diagnosed in 
3.2% of patients compared to 4.5% in the second group [81].
The incidence of cancers is higher in patients with sig-
nificantly increased D-dimer levels during the initial disease 
phase [82–85], and in patients with bilateral DVT [84] and 
with early relapse of VTE [86].
Guidelines: 
1. Routine extended diagnostic assessment towards 
malignant disease in every patient with an episode of 
idiopathic VTE is not recommended. This procedure 
could be indicated in elderly patients, with significantly 
increased D-dimer levels during initial disease phase, 
and in patients with bilateral DVT and with early relapse 
of VTE [2C].
2. Detailed physical examination and basic diagnostic 
tests, including chest X-ray, faecal occult blood test, 
urological examination in men, and gynaecological 
examination in women should be performed in every 
patient with an episode of idiopathic VTE [2C].
3. In patients with VTE and with justified clinical suspicion 
of malignant disease the diagnosis should be extended 
towards cancer (CT, endoscopic evaluations, abdominal 
US, cancer-related markers) [2B].
4. Prevention of VTE in patients with cancers 
treated non-surgically
4.1. Prevention of VTE in hospitalised, medically ill 
cancer patients
Three large RCTs, including cancer patients (5–15%), in-
dicated that antithrombotic prevention in acutely ill patients, 
immobilised in hospital settings, significantly decreased the 
incidence of VTE as compared to placebo, with low bleeding 
rates after use of LMWHs or fondaparinux [87–89]. Some can-
cer patients are hospitalised without any other acute diseases. 
In those cases, the Padua Prediction Score could be helpful 
to estimate the risk of VTE (Table II) [90].
There is a lack of unambiguous data from clinical studies 
regarding the use of routine antithrombotic prevention in 
patients hospitalised for cancer diagnosis or to administer 
short-term intravenous infusion of anticancer drugs. In those 
cases the decision of antithrombotic prevention initiation 
should be made individually.
Guidelines:
1. Antithrombotic prevention with LMWHs, UFH (subunit 
2.5), or fondaparinux in hospitalised, medically ill cancer 
patients is recommended [1A].
2. In hospitalised, medically ill cancer patients with pre-
vious VTE episodes, or in those immobilised or with 
venous blood flow from a lower body part blocked 
by a growing tumour, antithrombotic prevention 
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with LMWHs, UFH, or fondaparinux (subunit 2.5) is 
recommended, provided there are no contraindications to 
pharmacological antithrombotic prevention or high risk of 
haemorrhagic complications (subunit 2.6) [1C].
3. In hospitalised cancer patients with increased risk of VTE, 
use of mechanical antithrombotic prevention should be 
considered (PUP and PESU — subunit 2.7) [2C].
4. Routine antithrombotic prevention is not recommended 
in cancer patients hospitalised for diagnostic evaluation 
or for administration of short-term intravenous infusion 
of cytotoxic drugs [2C].
5. Pharmacological antithrombotic prevention is not rec-
ommended in cancer patients with current bleeding or 
with high risk of bleeding (subunit 2.6). In those cases, 
mechanical antithrombotic prevention (PUP and PESU 
— subunit 2.7) is recommended.
6. It is recommended not to use acetylsalicylic acid (ASA) 
as a single method of antithrombotic prevention during 
hospitalisation [2C].
4.2. Prevention of VTE in outpatients undergoing 
non-surgical anticancer treatment
Prevention of VTE should be introduced only in patients 
with increased risk of that disorder. For this reason, the scale 
of VTE risk assessment in cancer patients receiving chemo-
therapy in outpatient settings (the so-called Khorana Risk 
Score) was developed and validated (in the PROTECHT and 
SAVE-ONCO studies) (Table III) [91–93]. According to this 
score, patients are divided into three groups, e.g. with low 
(0 points), moderate (1–2 points), and high (more than 3 
points) risk of VTE induced by chemotherapy (Table II). VTE 
risk in particular groups accounts for 0.3%, 2%, and 6.7%, 
respectively. This predictive model allows identification of 
the patients with high risk of VTE [2B]. The Khorana Risk 
Score (Table III) does not include poor general patient state 
and some types of cancers connected to high risk of VTE, 
for example brain tumours. 
The Khorana Risk Score of VTE risk in cancer patients 
undergoing chemotherapy was modified by Ay et al. [94]. 
They added serum P-selectin and D-dimer levels to five 
parameters covered by the original model. The probability 
of symptomatic or fatal VTE is then 35% in patients with ≥ 5 
risk factors, 10.3% with 3 risk factors, and 1.0% with no risk 
Table II. Assessment of risk factors of venous thromboembolism (VTE) in hospitalised patients — Padua Prediction Score [90]
Risk factors Score
Active malignant disease (patients with metastases to regional lymph nodes or with distant metastases, undergoing chemotherapy or 
radiotherapy during the last 6 months) 
3
Past VTE (except thrombosis of superficial veins) 3
Immobility (assumed need for staying in bed [with possibility of using bathroom/toilet] due to patient’s disability or physician order 
for ≥ 3 days)
3
Diagnosed thrombophilia (antithrombin, protein C or S deficiency, mutation of factor V Leiden, mutation G20210A  
in prothrombin gene or antiphospholipid syndrome)
3
Recently past (≤ 1 month) injury or surgery 2
Age ≥ 70 years 1
Heart or respiratory failure 1
Recent myocardial infarction or ischaemic stroke 1
Acute infection or rheumatic disease 1
Obesity (BMI ≥ 30 kg/m2) 1
Hormone therapy 1
Total result ≥ 4 points indicates high risk of VTE 
Total result < 4 points indicates low risk of VTE
VTE — venous thromboembolism; BMI — body mass index
Table III. Khorana Risk Score (with ASCO modification) of venous 
thromboembolism risk in outpatients undergoing chemotherapy [8, 91]
Risk factors Score
Target organ and histological type
Very high risk
   • gastric adenocarcinoma
   • pancreatic adenocarcinoma
   • malignant brain tumours
2
High risk
   • lung cancer
   • lymphomas
   • gynaecological cancers
   • bladder cancer
   • testicular cancer
   • kidney cancer
1
Haematological risk factors
   • platelets count before chemotherapy ≥ 350 G/l
   • haemoglobin level < 10 g/dl or ESA using
   • leucocyte count before chemotherapy > 11 G/L
1
1
1
Patient-related factors
   • BMI ≥ 35 kg/m2 1
ESA — erythropoiesis stimulating agents; BMI — body mass index
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factors. The limitation of the modified score is that P-selectin 
is not routinely assessed in clinical practice and there are no 
tests registered for clinical use.
To date there is no strong evidence justifying routine an-
tithrombotic prevention in patients undergoing radical ra-
diotherapy or radiochemotherapy or palliative radiotherapy. 
Guidelines:
1. Routine antithrombotic prevention in cancer patients 
undergoing chemotherapy in outpatient settings is not 
recommended [2C].
2. Antithrombotic prevention could be considered in pa-
tients undergoing chemotherapy in outpatient settings 
with high risk of VTE, e.g. in patients with advanced 
pancreatic cancer [1B] or non-small cell lung cancer 
(NSCLC), provided that they have low risk of bleeding 
and no contraindications to anticoagulants [2B].
3. Every patient with multiple myeloma should be assessed 
for VTE risk (subunit 3.1) and receive appropriate anti-
thrombotic prevention [1A].
4. Patients with multiple myeloma are recommended to 
receive the following VTE prevention [62]:
 a. ≤ 1 VTE risk factor: ASA in the dose of 100 mg/d [1B];
 b. ≥ 2 VTE risk factors: LMWHs in prophylactic dose or 
VKA with target INR value between 2.0–3.0 [1B];
 c. LMWH should be administered for at least four 
months and then could be replaced by ASA [2C].
5. In the remaining patients undergoing chemotherapy 
in outpatient settings the decision of antithrombot-
ic prevention initiation should be made individually, 
based on analysis of VTE risk (subunit 3.1) and individual 
assessment of benefits and possible complications of 
such prevention.
6. It is recommended that ASA is not used as the single 
method of antithrombotic prevention [2C].
7. In cancer patients undergoing chemotherapy in outpa-
tient settings with increased risk of VTE use of PUP and 
PESU should be considered (subunit 2.7).
8. Routine antithrombotic prevention in patients under-
going radical radiotherapy, radiochemotherapy, or pal-
liative radiotherapy is not recommended.
9. In patients during radical radiotherapy, radiochemother-
apy, or palliative radiotherapy the decision of antithrom-
botic prevention initiation should be made individually 
with consideration of VTE risk factors, associated with 
general patient’s state, concomitant diseases, cancer 
type and stage, and combination of radiotherapy with 
systemic treatment.
4.3. Antithrombotic prevention in patients with 
indwelling central venous catheter
Clinically overt subclavian artery thrombosis occurs in 
approx. 5% of patients; however, incidental for of that disor-
der is diagnosed in up to 14–18% of patients with indwelling 
central venous catheters [95]. There is no evidence of LMWH 
or VKA efficacy in VTE prevention in patients with indwelling 
central venous catheters [96].
Guidelines:
1. Routine antithrombotic prevention in cancer patients 
with indwelling central venous catheters is not recom-
mended [2C].
2. Catheters should be inserted on right body side; how-
ever, the catheter’s end should be placed close to the 
superior vena cava-right atrium junction in order to 
decrease the risk of thromboembolic complications [2C].
3. Antithrombotic prevention in patients with high VTE 
risk should be individualised [2C].
4.4. Prevention of VTE in patients with 
concomitant thrombocytopaenia
Guidelines of antithrombotic prevention use in patients 
with thrombocytopaenia are based on data from obser-
vational studies, conducted in relatively small groups of 
patients treated in single centres [97–103]. In this group of 
patients mechanical VTE prevention methods could be used, 
except for pharmacological antithrombotic prevention. 
Guidelines:
1. In acutely ill patients with active cancer, hospitalised due 
to non-surgical disease, pharmacological VTE preven-
tion is recommended in standard doses, provided that 
platelet count is ≥ 50 G/l and there are no symptoms of 
haemorrhagic diathesis and no additional haemostasis 
disorders [2C].
2. When the platelet count is 25–50 G/l and there are no 
symptoms of haemorrhagic diathesis the decision of 
using anticoagulants in standard doses or their decrease 
or abandonment of antithrombotic prevention should be 
based on analysis of potential benefits and risk resulted 
from the therapy [2C].
3. In patients with platelet count < 25 G/l it is suggested 
not to use antithrombotic prevention, and in this case 
mechanical antithrombotic prevention methods (PUP 
and PESU — subunit 2.7) could be used [2C].
4. When thrombocytopaenia is accompanied by active 
haemorrhagic diathesis and/or concomitant haemosta-
sis disorders it is suggested not to use pharmacological 
antithrombotic prevention. In this case mechanical VTE 
prevention methods are recommended (PUP and PESU 
— subunit 2.7).
5. The above recommendations relate also to cancer 
patients with concomitant thrombocytopaenia, who 
needed antithrombotic prevention for reasons other 
than hospitalisation due to acute non-surgical disease, 
e.g. outpatients.
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4.5. Antithrombotic prevention in patients  
with concomitant renal insufficiency 
During chronic renal disease with declined eGFR not 
only pharmacokinetics of anticoagulant drugs excreted by 
the kidney (LMWHs, fondaparinux, DOAC), but also plasma 
protein binding and distribution volume are changed. The 
risk of bleeding complications in patients with impaired 
renal function during use of anticoagulants is increased 
due to decreased clearance of the drugs and their pro-
longed activity. Other factors increasing the risk of bleed-
ings include: older age, obesity, and concomitant use of 
antiplatelet drugs. There is a lack of large, prospective RCTs 
assessing the efficacy and safety of anticoagulant drugs 
in this group of patients. Thus, the potential benefits and 
bleeding risk during use of anticoagulants in patients 
with impaired renal functions should always be assessed 
individually.
Guidelines [23, 104, 105]: 
1. In patients with impaired renal function (eGFR < 30 ml/
min) UFH in the dose of 5000 IU s.c. every eight hours 
is preferred because elimination half-life of LMWHs and 
fondaparinux is prolonged in renal insufficiency, and 
those drugs could be accumulated in plasma [2C]. 
 a. When long-term administration of LMWHs is in-
dicated in patients with impaired renal function 
the measurement of anti-Xa activity during dose 
establishment in serum from blood sample obtained 
four hours after LMWH injection could be helpful 
to decrease bleeding risk. Target value of anti-Xa 
should not exceed 0.5 IU/ml;
 b. Administration of LMWH in doses reduced by half 
is an alternative.
2. In patients with high risk of bleeding, who need anti-
thrombotic prevention, mechanical preventive methods 
(PUP and/or PESU) are recommended. 
4.6. Antithrombotic prevention in terminally ill 
cancer patients treated in hospices
Patients in advanced cancer stage treated in hospices 
are classified into the group of high VTE/PE risk, among 
others due to older age, advanced loco-regional disease 
(vascular stasis caused by external pressure of large tumour 
mass leads to blood flow disturbance and favours VTE), or 
massive distant metastases as well as reduced patient mo-
bility [106]. Clinically overt PE develops in approx. 10% of 
hospice patients [106]. Additionally, it is estimated that half 
of stationary hospice patients report clinically asymptomatic 
DVT [107, 108]. Those patients receive different drugs, which 
could additionally increase the risk of VTE, e.g. megestrol, 
commonly used in cancer patients with cachexia, associ-
ated with 30% risk of complications, mainly DVT of lower 
extremities. The main benefit of antithrombotic prevention in 
patients treated in hospices, where the best possible quality 
of life is a priority but not obstinate life prolongation, could 
be reducing the risk of VTE symptoms occurrence, including 
pain, oedema, or dyspnoea [106]. However, there is a lack of 
clinical studies conducted in the patient groups with appro-
priate sample sizes, which could unambiguously assess the 
influence of antithrombotic prevention on VTE symptoms 
or survival of hospice the patients [109].
Antithrombotic prevention in cancer patients treated 
in hospices is a challenge for many reasons: unknown in-
fluence of quality of life, unclear risk of VTE after cessation 
of antithrombotic prevention, bleeding risk, additionally 
increased in malnourished patients and in patients with 
reduced eGFR, interactions of many drugs with VKA, and 
direct and indirect costs of that management [110–113]. 
Guidelines:
1. Routine antithrombotic prevention in all cancer patients 
treated in hospices is not recommended [2C].
2. In every patient the decision about antithrombotic 
prevention initiation should be made individually, con-
sidering VTE risk, co-morbidities, and bleeding risk [2C].
4.7. Prevention of VTE in pregnant women 
diagnosed with cancer 
Indications to VTE prevention in pregnant women with 
cancer are the same as in other cancer patients. Pregnancy 
increases the risk of VTE occurrence; however, other concom-
itant VTE risk factors in pregnant women with cancer justify 
initiation of antithrombotic prevention. Similarly to general 
antithrombotic prevention in cancer patients, LMWHs and 
UFH are preferred in pregnant women because those anti-
coagulants do not cross the placenta, unlike VKA. VKAs are 
contraindicated during the first three months of pregnancy 
(due to teratogenic effect), but also during second and third 
trimester they are reluctantly used as they increase risk of 
bleeding in the mother and especially in the foetus. DOACs 
are contraindicated during pregnancy [114]. Fondaparinux is 
not indicated during pregnancy, but there are single reports 
indicating its safety and efficacy in VTE prevention in pregnant 
women, e.g. in the case of HITT occurrence.
Elective caesarean section is very rarely complicated 
by VTE, so routine antithrombotic prevention is indicated 
when there are additional risk factors (e.g. cancer) [115, 116].
Guidelines:
1. Indications to VTE prevention in pregnant women with 
cancer are the same as in other cancer patients.
2. LMWHs and UFH are the preferred anticoagulants in 
antithrombotic prevention in pregnant women with 
cancer [2C].
3. Dosing of LMWHs and UFH in pregnant women with 
cancer is the same as in other cancer patients. However, 
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in the case of additional risk factors, e.g. obesity, previ-
ous VTE episode, or concomitant congenital thrombo-
philia/antiphospholipid syndrome, higher LMWH doses 
(even therapeutic) could be recognised, based on an-
ti-Xa activity when necessary [2C].
4. In pregnant women with cancer undergoing caesarean 
section, pharmacological antithrombotic prevention in 
standard doses should be used [2C].
5. After occurrence of active haemorrhagic diathesis, deep 
thrombocytopaenia, or other haemostasis disturbances, 
increasing the bleeding risk in pregnant women with 
cancer and high VTE risk mechanical preventive meth-
ods (PUP, PESU — subunit 2.7) should be considered.
5. Treatment of cancer patients with VTE
The aim of VTE treatment in cancer patients is prevention 
of acute and chronic complications. Cancer patients have a 
2–5-fold increased risk of VTE recurrence and 2–6-fold in-
creased risk of major bleedings as compare to the population 
of patients with VTE but without cancer [1–4]. Every time, 
the bleeding risk (subunit 2.6) and potential benefits from 
antithrombotic treatment should be balanced [13, 108]. 
Very often, fast appropriate diagnosis of PE and initi-
ation of adequate treatment are of extreme importance 
for the further life of patients with PE complicating the 
clinical course of cancer [13, 24, 109–111]. The majority of 
PE cases are embolisms that do not require thrombolytic 
treatment. The treatment of patients with PE is based on 
procedures aiming at restoration of pulmonary vasculature 
patency, reduction of VTE recurrence risk, and maintaining 
appropriate perfusion and oxygen delivery to important 
organs and systems, despite haemodynamic and respiratory 
disturbances caused by PE. There are two main periods 
of PE treatment: initial and long, chronic antithrombotic 
treatment, continued for many months. 
5.1. Initial treatment of cancer patients with VTE  
or PE with no need for thrombolytic therapy
The efficacy of LMWHs during initial VTE treatment was 
comparable to UFH, with lower risk of bleeding compli-
cations [117–123]. It was observed in Cochrane analysis 
including cancer patients that the efficacies of LMWHs, 
UFH, and fondaparinux during initial VTE treatment were 
comparable [124]. 
During initial treatment of cancer patients with concom-
itant VTE not requiring thrombolytic therapy therapeutic 
doses of heparins (LMWHs, UFH) or fondaparinux are used. 
LMWHs are the most frequently used drugs during PE treat-
ment in cancer patients, but only in patients with high risk PE 
therapy starts with infusion of UFH followed by thrombolytic 
treatment [75, 125–133]. 
The percentage of cancer patients in RCTs regarding 
efficacy and safety of DOAC during initial treatment of VTE 
was low (< 10%), so those drugs should not be used in 
this phase of therapy in cancer patients with concomitant 
VTE. Unfractionated heparin is still the backbone drug in 
patients with clinically justified suspicious or confirmed 
diagnosis of VTE. It should be used in optimal doses be-
cause it was shown that inadequate APTT prolongation 
(or insufficient increasing of anti-Xa activity) within the 
first 24 hours of treatment could increase VTE risk by even 
more than ten times [40]. On the other hand, it was also 
proven that administration of UFH in continuous infusion 
in total daily dose exceeding 30,000 or 35,000 IU protects 
the patient against recurrence of VTE, regardless of APTT 
value. Fondaparinux is another drug used during the initial 
phase of VTE treatment. The MATISSE PE study [133] indi-
cated that fondaparinux is safe and efficacious in patients 
with PE, similarly to UFH.
Abandonment of antithrombotic treatment (for many 
reasons, e.g. high bleeding risk) or overlooking the throm-
bus in angio-CT scans in patients with incidental VTE led to 
increased mortality [134]. 
ACCP guidelines recommend using of antithrombotic 
treatment in cancer patients with accidental diagnosis of 
DVT or PE [135].
Guidelines: 
1. Treatment of DVT or PE in cancer patients is similar to 
that used in non-cancer patients. 
2. Cancer patients with concomitant DVT or PE, who do 
not require thrombolytic treatment, could be treated 
in outpatient settings, provided that the following 
conditions are fulfilled [39]: stable clinical patient’s 
state, adequate basic vital signs, low bleeding risk, 
serum creatinine concentration below 150 µmol/l or 
eGFR over 60 ml/min, ensured system of antithrombot-
ic drugs administration and professional supervision 
by trained nurse or physician towards bleeding com-
plications, efficacy of antithrombotic treatment, and 
recurrence of VTE.
3. Cancer patients with concomitant extensive, proximal 
DVT, or PE requiring either antithrombotic therapy or 
embolectomy should be treated in hospital settings.
4. Every time, bleeding risk and potential benefits of anti-
thrombotic treatment should be balanced. 
5. LMWHs given s.c. are recommended during initial treat-
ment in the majority of cancer patients diagnosed with 
VTE (subunit 2.5.1) [1B].
6. During LMWH treatment, moderate patient activity is 
recommended [2C].
7. Patients with VTE are recommended to be mobilised 
with simultaneous using of pressure therapy (PUP, PESU 
— subunit 2.7), provided that there are no contraindi-
cations. Periodic control of local state and tolerability of 
pressure therapy is also recommended [2C].
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8. In cancer patients with contraindications to LM-
WHs treatment with UFH (IV or s.c.) (subunit 2.5.2) or 
fondaparinux (subunit 2.5.3) is recommended [2C].
9. DOAC are not recommended during initial treatment of 
cancer patients with concomitant VTE [2C].
10. Thrombolytic treatment (subunit 2.8) in cancer patients 
with concomitant DVT should be considered only in cas-
es with massive limb-threatening changes in iliofemoral 
vessels. Good prognosis (expected survival time at least 
one year), low bleeding risk, and no contraindications to 
thrombolytic treatment are necessary conditions. De-
scribed management should be initiated no later than 
14 days after onset of clinical symptoms [2C]. In the 
abovementioned case the drugs should be administered 
during 1–2 days in very low doses through a catheter 
inserted inside the thrombus. Systemic thrombolytic 
treatment could be used in specific situations, among 
others when the thrombolytic drug cannot be deliv-
ered inside the thrombus due to lack of an experienced 
treating team.
11. In patients with incidental VTE the management should 
be the same as during symptomatic VTE [2C].
5.2. Initial treatment of cancer patients with PE 
with need for thrombolytic therapy
UFH IV is recommended during initial treatment of this 
group of patients. In justified cases LMWHs could be consid-
ered. There are very few reports of using LMWHs in patients 
with PE requiring thrombolytic treatment but their results 
are quite encouraging.
In patients with shock induced by PE thrombolytic 
treatment should be introduced. However if it fails or could 
not be used, surgical embolectomy should be considered 
or transdermal treatment through catheter. Thrombolytic 
drugs should be used in patients with PE and concomitant 
shock or severe hypotension (preshock state is defined as 
decline of systolic blood pressure by 40 mm Hg during 15 
minutes). In patients with cardiac arrest thrombolytic drugs 
could be difficult to administer. However, if a patient with 
cardiac arrest is in intensive care room and potential cause 
of this state could be PE, thrombolytic treatment during 
cardiopulmonary resuscitation could be possible. In pa-
tients with PE thrombolytic drugs should be administered 
to peripheral veins. It was not shown that administration of 
thrombolytic drugs directly to pulmonary artery improves 
outcomes. 
Pulmonary embolectomy with extracorporeal circu-
lation in normo- or hypothermia is the basic surgical 
method of treatment of acute PE, with death risk of 6% 
in experienced medical centers. It allows detailed assess-
ment and removal of thrombotic tissue from the right 
ventricle, right atrium, as well as the pulmonary artery 
[136, 137].
In the subgroup of patients with absolute contraindi-
cations to anticoagulation or after PE recurrence despite 
thrombolytic treatment, venous filters should be considered, 
which protect pulmonary circulation against in-flowing 
thrombi from deep veins of lower and upper extremities. 
Filters also reduce PE risk and subsequently cardiac arrest 
risk and death, but could additionally increase the risk of 
post-thrombotic syndrome (PTS) [137, 138].
In all patients with PE requiring thrombolytic treatment, 
adequate supportive care is needed.
Guidelines:
1. Initial treatment of cancer patients with concomitant 
PE requiring thrombolytic treatment or embolectomy 
should be conducted in hospital settings [1C].
2. In patients with planned thrombolytic treatment UFH 
should be used as initial treatment (subunit 2.5 and 
5.1) [1C].
3. In treatment of cancer patients with PE during the first 
month of therapy and after stabilisation of patient’s state 
LMWHs are recommended and administered in thera-
peutic doses in two injections daily, which reduces the 
bleeding complication rate compared to administration 
of those drugs once daily only (subunit 2.5.1).
4. In cancer patients with concomitant high-risk PE, throm-
bolytic drugs are recommended (subunit 2.8), provided 
that there are no contraindications.
5. Thrombolytic drugs are recommended to be admin-
istered to peripheral veins but not to the pulmonary 
artery.
6. When recombinant tissue plasminogen activators (rt-
PAs) cannot be used in patients with PE and shock or 
hypotension, streptokinase should be introduced (sub-
unit 2.8). After cessation of thrombolytic treatment, UFH 
infusion should be initiated with an initial rate of 1000 
IU/hour, continuing antithrombotic therapy according 
to general rules (subunit 2.5.2). 
7. Recurrence of PE requiring thrombolytic treatment in 
patients with previous SK treatment (between four days 
and nine months) is an indication to rt-PA (subunit 2.8).
8. In patients with cardiac arrest, possibly as a result of PE 
requiring thrombolytic treatment, a rt-PA bolus should 
be used (subunit 2.8). The advantage of an rt-PA bolus 
over two hours of SK therapy is based on possibly faster 
reduction of pulmonary resistance after rt-PA. 
9. 12-hour administration of thrombolytic drugs in cancer 
patients with concomitant PE is not recommended be-
cause such long treatment duration is associated with 
unacceptable increase in bleeding rate in this group 
of patients. 
10. In patients with shock resulting from PE requiring throm-
bolytic treatment after failure of thrombolytic drugs, 
pulmonary embolectomy should be considered.
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11. Indications to pulmonary embolectomy are as follows:
 a. shock and massive obturation of pulmonary artery 
in patients with contraindications to thrombolytic 
treatment (early period after surgical procedure or 
intra-operative embolism); 
 b. failure of thrombolytic treatment [21, 23]. 
12. In some cancer patients with concomitant PE, implan-
tation of inferior vena cava filter should be considered.
13. Indications to implantation of inferior vena cava filter 
are as follows:
 a. initiating or continuation of PE causative treatment 
is impossible due to contraindications or treatment 
complications;
 b. PE treatment according general rules failed, with 
signs of PE recurrence;
 c. status after embolectomy or planned thrombo-
endarterectomy without any contraindications to 
anticoagulation. 
14. Specific indications to implantation of retrievable in-
ferior vena cava filter associated with PE risk could be 
considered in exceptional cases. It relates to patients 
with absolute contraindications to pharmacological 
thrombolytic treatment, occurrence of complications 
after thrombolytic treatment, or failure of adequately 
conducted thrombolytic treatment [23]. 
15. In all patients, adequate supportive therapy is neces-
sary, which very often has extreme importance for the 
patient’s further life: 
 a. all patients with PE and with shock, significant de-
cline of blood pressure, respiratory failure, significant 
overloading of right ventricle, or cardiac arrhythmia 
need to be treated in intensive supervision units; 
 b. in case of shock, invasive blood pressure monitoring 
(haemodynamic line) is essential;
 c. patients with acute respiratory distress should have 
adequate oxygen supply — in most cases nasal 
canola or mask precisely maintaining specific ox-
ygen concentration in gas mixture is sufficient;
 d. in case of advanced, acute disorders, therapy with 
techniques of non-invasive ventilation should be 
initiated, and in exceptional cases intubation and 
mechanical ventilation is indicated; 
 e. in patients with hypotension or shock, catechol-
amines should be administered. The treatment 
should be initiated with dopamine, and if it fails 
noradrenalin and dobutamine are used. 
5.3. Long-term and chronic treatment of cancer 
patients with VTE 
RCTs (LITE, CLOT, ONCENOX, CANTHANOX) and me-
ta-analyses indicate that LMWHs used in long-term treat-
ment is associated with approx. 50% reduction of VTE 
recurrence rate as compared to VKA administration with 
similar bleeding risk [46, 118–124, 135]. The CLOT study 
was a breakthrough clinical trial, assessing the efficacy 
and safety of LMWHs in VTE treatment in cancer patients 
[123]. Cancer patients suffering from DVT and/or PE re-
ceived dalteparin in the dose of 200 IU/kg b.w. once daily 
for 5–7 days and VKA (to maintain INR between 2.0–3.0) or 
dalteparin in the dose of 200 IU/kg b.w. once daily during 
the first month, and then 150 IU/kg b.w. once daily during 
next five months. The probability of VTE recurrence during 
six months of follow-up was 17% in the group receiving 
VKA and 9% in patients with long-term treatment with 
dalteparin [hazard ratio (HR) 0.48, P = 0.002]. There were no 
differences in major bleeding rates and mortality between 
both groups. Two other studies [121, 122] confirmed efficacy 
of enoxaparin and tinzaparin in the chronic treatment of 
VTE in cancer patients as compares to initial therapy with 
LMWHs followed by VKA. Systematic review and Cochrane 
analysis comparing efficacy of LMWHs and VKA in long-
term treatment showed decreased VTE recurrence rate af-
ter LMWHs compared to patients receiving VKA (RR 0.49; 
95% CI 0.34–0.70) with similar bleeding rate [46]. Addition-
ally, it was indicated that use of only full or medium but 
not prophylactic dose of LMWH shows advantages over 
VKA administration in prevention of VTE recurrences [121]. 
Furthermore, RTCs and meta-analyses showed the advan-
tages of LMWHs over VKA in chronic treatment (up to six 
months) [46, 118–120].
Based on results of the LITE, CLOT, ONCENOX, and CAN-
THANOX studies on VTE treatment in cancer patients, it 
was noted that initial therapy with therapeutic doses of 
LMWHs should be prolonged up to at least one month, 
and then reduction of LMWH dose to 75–80% of baseline 
therapeutic dose should be consider or full doses of LMWH 
should be continued at least during the first three months 
of treatment [118–123]. 
Optimal duration of LMWHs treatment in cancer pa-
tients who experience DVT is still debatable. Continuation 
of antithrombotic treatment beyond 3–6 months and the 
means of its administration should be taken individually, 
considering the risk of VTE recurrence and possible compli-
cations. The DALTECAN study, including 334 cancer patients 
with concomitant VTE, indicated that use of dalteparin for 
the first month in the dose of 200 IU/kg body weight (no 
more than 18,000 IU) and then its continuation for 2 to 12 
months in the dose of 7,500 IU in patients with body weight 
not higher than 56 kg, 10,000 IU in patients with body weight 
between 56–68 kg, 15,000 IU in patients with body weight 
between 83–98 kg, and 18,000 IU in patients with body 
weight over 99 kg, was associated with low bleeding rate 
(10.2% of patients), but the highest bleeding risk was ob-
served during the first month of antithrombotic treatment 
[139]. VTE recurrences were reported in 11.1% of patients 
(5.7% during the first month, 1.34% during 2–6 months, 
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and 4.1% during 7–12 months). However, analysis of data 
from the RIETE database indicated that among 7,911 cancer 
patients (in active stage) undergoing antithrombotic treat-
ment for a mean period 181 days (± 210 days) PE recurrences 
were observed in 178 patients and DVT recurrences in 194 
patients, whilst in 367 patients bleedings were reported. 
Among 4,125 patients with PE 45 patients died from PE 
recurrence, and 45 from bleeding. However, among 3,786 
patients with previous DVT — 19 patients died from PE, and 
55 patients dies due to bleeding [13].
Risk of VTE recurrence can be assessed according to the 
Louzada score (Table IV) [140].
Prolongation of LMWHs administration beyond six 
months in the treatment of first VTE episode in cancer 
patients should be considered in patients with stage IV 
malignant brain tumours, lung, ovarian, gastrointestinal 
cancer, with metastases to bone marrow and dysplasia of 
bone marrow, or with paresis of extremities and stage III 
neurological syndromes [141].
The beneficial influence of LMWHs on decreasing VTE 
recurrence rate is observed only during their administra-
tion and does not transfer to the period after cessation of 
antithrombotic treatment [142]. The duration of chronic 
treatment depends on the presence of VTE risk factors and 
should last as long as they maintain. In some patients there 
is a consistently increased risk of VTE recurrence, suggesting 
some benefits from indefinite antithrombotic treatment, 
e.g. in the case of active cancer. In patients with transient 
risk factor (e.g. immobilisation) the risk of VTE recurrence 
decreases with time.
LMWHs and UFH are used in the treatment of cancer 
patients with VTE [24]. Administration of ASA is suggested 
after cessation of antithrombotic treatment, but there are 
very few data regarding such management in cancer pa-
tients [143, 144]. 
DOAC showed similar efficacy in VTE treatment as com-
pared to standard therapy with heparin and then warfarin, 
as well as similar bleeding risk in subanalyses of large clinical 
studies with those drugs in VTE treatment [145]. However, 
these observations are based on studies with small sample 
sizes (cancer patients accounted for 5% of the total group on 
average, and they were even excluded from some studies). 
There was no significant advantage of one DOAC drug over 
another in comparative analyses of cancer patients. There 
are also available data suggesting lower VTE recurrence risk 
in cancer patients receiving DOAC in acute disease phase, as 
compare to standard treatment, most likely in connection 
with better stability of anticoagulation compared to warfa-
rin, resulting from lack of diet influence and rare drug-drug 
interactions [146]. Malignant disease with high bleeding risk 
is a contraindication to DOAC treatment. Thus, based on 
observational studies DOAC could be a therapeutic option 
in cancer patients treated for VTE when other drugs, espe-
cially heparin, are not tolerated or are ineffective, or due to 
patient’s preferences, e.g. in patients with hypersensitivity to 
LMWHs or after HITT episode. Use of DOAC in cancer patients 
is discouraged, especially in elderly patients, having higher 
bleeding risk. Major bleeding risk, mainly from the gastroin-
testinal tract, is a relative contraindication to DOAC because 
those drugs are active in the gastrointestinal tract, which 
increases the risk of the complication as compared to other 
anticoagulants. Anticancer drugs metabolised through 3A4 
cytochrome or transported by P-glycoprotein [bortezomib, 
cyclosporine, dexamethasone, most of tyrosine kinase in-
hibitors (TKIs), tamoxifen, some immunomodulatory drugs, 
supportive drugs (e.g. fentanyl, methadone, clonazepam, 
ondansetron, aprepitant, and fosaprepitant)] intensify antico-
agulation effects of DOAC and increase bleeding risk. Thereby, 
in this group of patients, measurement of blood drug con-
centrations could be very useful [147]. In Europe dabigatran 
is not recommended in patients treated with cyclosporine 
or tacrolimus — potent inhibitors of P-glycoprotein. Patients 
with eGFR below 30 ml/min or worsening kidney functions 
should not be treated with DOAC to decrease major bleeding 
risk. eGFR monitoring 2–3 times yearly improves the safety 
of DOAC treatment. Periodical monitoring of liver function 
and complete blood count including platelet count is also 
recommended in patients treated with DOAC.
To date, treatment with DOAC was not assessed in RCTs 
in cancer patients suffering from VTE [148–151].
Guidelines:
1. LMWHs are preferred in long-term and chronic treat-
ment of cancer patients with VTE over VKA [1A] or DOAC 
[2C].
2. Considering high VTE recurrence risk, initial therapy 
with therapeutic doses of LMWHs (subunit 2.5.1) in 
cancer patients with VTE should be prolonged up to at 
least one month, and then reduction of LMWH dose to 
75–80% of baseline therapeutic dose should be consid-
ered or full doses of LMWH should be continued at least 
during the first three months of treatment (long-term 
treatment) [1A].
Table IV. The Louzada score for assessment of the risk of venous 
thromboembolism recurrence in cancer patients [140] 
Risk factor Score
Female gender 1
Lung cancer 1
Breast cancer –1
TNM, CS I –2
Previous VTE 1
Score: ≤ 0 — low recurrence risk; ≥ 1 — high recurrence risk
TNM — classification of cancer clinical stage (T — tumour, N — lymph node, M 
— metastases); CSI — clinical stage I
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3. DOAC should not be used in VTE treatment in cancer 
patients, unless other drugs cannot be used or they 
are insufficient or this decision is based on the patient’s 
preferences. 
4. Long-term antithrombotic therapy is recommended in 
cancer patients after PE. After one month of initial treat-
ment chronic LMWH therapy should be continued for 
the next five months, with use of 75–80% of therapeutic 
dose (subunit 2.5.1). 
5. Beyond six months after past PE, treatment with LMWH 
could be continued if still indicated.
6. Drugs from the VKA group could be used as needed after 
six months of LMWH administration. Target INR values 
should be in the range between 2.0–3.0 (subunit 2.5.4). 
7. In patients with PE complicated by chronic pulmonary 
hypertension, chronic treatment should be adminis-
tered for an indefinite period.
8. When there is no possibility to use, or there are contra-
indications to, long-term administration of LMWH in 
cancer patients VKA therapy is suggested as an alter-
native management (subunit 2.5.4) [1B].
9. In patients with active cancers, LMWHs or VKA could be 
chronically used, if not contraindicated, with periodical 
assessment towards the need to continue antithrombot-
ic therapy (at least one per year) [2C].
10. Antithrombotic drugs should be administered until the 
patient’s recovery from cancer or until the end of life 
when the cancer is not curable. 
11. In patients with symptomatic thrombosis of mesenteric 
or hepatic veins antithrombotic treatment should be 
used, but in case of accidental diagnosis it is suggested 
not to initiate a therapy. 
12. Cancer infiltration of the pericardium requires that anti-
thrombotic treatment be conducted with caution.
13. In patients with primary brain malignant tumours and 
concomitant VTE, antithrombotic treatment is recom-
mended as in cancer of other localizations, but the pa-
tient should be monitored more frequently in order to 
avoid bleeding complications.
14. When paracentesis or other surgical procedures are 
planned in cancer patients treated with VKA, oral anti-
thrombotic treatment should be interrupted and instead 
LMWHs should be used.
15. When VTE is diagnosed during anticancer non-surgical 
treatment, chemotherapy and/or radiotherapy should 
be continued with concomitant administration of ap-
propriate antithrombotic treatment in adequate doses, 
unless there are any special conditions. 
16. In cancer patients with concomitant VTE requiring sur-
gical operation the best decision would be to postpone 
the procedure by up to three months, but if impossible, 
implantation of a retrievable inferior vena cava filter 
could be considered, if VTE is presented as proximal 
DVT of lower extremities.
17. In breast cancer patients treated with tamoxifen with 
concomitant VTE it is recommended to replace this drug 
with an aromatase inhibitor, and then after administra-
tion of LMWHs in full doses, continuation of treatment 
with 75–80% of baseline doses should be considered 
(subunit 2.5.1). 
18. In cancer patients with concomitant VTE during ad-
juvant chemotherapy after administration of LMWHs 
in full doses, continuation of treatment with 75–80% 
of baseline doses for the next six months should be 
considered (subunit 2.5.1).
19. In cancer patients with CR after systemic curative treat-
ment and with concomitant VTE during chemotherapy, 
after administration of LMWHs in full therapeutic dos-
es, continuation of treatment with 75–80% of baseline 
doses for the next six months should be considered 
(subunit 2.5.1).
20. In cancer patients during palliative chemotherapy achiev-
ing CR, even in patients with high cancer recurrence risk, 
the duration of chronic antithrombotic treatment should 
be discussed with patients on an individual basis.
21. In cancer patients with concomitant DVT (especially axil-
lary vein and more proximal veins), antithrombotic treat-
ment should be initiated as soon as possible; preferred 
drugs include LMWHs (subunit 2.5.1) and fondaparinux 
(subunit 2.5.3) administered for at least three months (if 
there is no central catheter) or continuously (when there 
is still an inserted central catheter).
22. Some patients need thrombolytic drugs to maintain 
the central catheter in the vein (e.g. after symptoms 
intensification, when thrombus occludes the majori-
ty of the lumen of the subclavicular and axillary vein, 
symptoms sustain longer than 14 days, the patient is in 
good general state, expected survival time exceeds one 
year, and there is low bleeding risk). 
5.4. Treatment of cancer patients with VTE and 
concomitant thrombocytopaenia
Venous thromboembolism can sometimes develop in 
cancer patients with concomitant thrombocytopaenia [96]. 
In order to establish optimal management, the following 
should be identified: 
 — cause of thrombocytopaenia (cancer infiltration of 
bone marrow, effect of chemotherapy, immunological 
thrombocytopaenia, drug-induced thrombocytopaenia, 
thrombotic microangiopathy, etc.);
 — severity of thrombocytopaenia (no signs of haemor-
rhagic diathesis vs. bleeding); 
 — expected duration time of thrombocytopaenia (tran-
sient vs. long-term); 
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 — presence of additional (except thrombocytopaenia) risk 
factors of bleeding (older age, kidney and liver insuffi-
ciency, etc.).
The choice of antithrombotic treatment and its intensity 
in those cases should be based on individual assessment of 
potential benefits and disadvantages associated with the 
use of anticoagulants [13, 152–154]. 
Guidelines: 
1. Use of therapeutic doses of antithrombotic drugs is 
recommended without transfusion of platelet concen-
trate if platelet counts in cancer patients with acute 
VTE episode are ≥ 50 G/l and there are no symptoms of 
haemorrhagic diathesis [2C].
2. In cases of acute VTE episodes in cancer patient with 
platelet count < 50 G/l but without symptoms of hae-
morrhagic diathesis:
 a. use of therapeutic doses of antithrombotic drugs is 
recommended with transfusion of platelet concen-
trate in order to maintain platelet count ≥ 50 G/l. If 
it is impossible to maintain target platelet count, 
a decision about the use of therapeutic doses of 
antithrombotic drugs or their reduction should be 
based on individual assessment of potential benefits 
and disadvantages of particular therapeutic options 
[2C];
 b. if transfusion of platelet concentrate allows main-
tenance of platelet count in the range between 
20–50 G/l, it is suggested to reduce the doses of 
antithrombotic drugs to 50% of therapeutic dose, 
but in clinically justified cases maintenance of ther-
apeutic doses could be favourable [2C]; 
 c. if platelet count drops below 20 G/l despite trans-
fusion of platelet concentrate, it is suggested to 
withdraw antithrombotic drugs [100] [2C].
3. In patients with limited clinical symptoms of haemor-
rhagic diathesis, without tendency to intensify during 
antithrombotic treatment, the above guidelines do not 
have to be modified.
4. In cases of acute VTE episodes in cancer patients with 
concomitant thrombocytopaenia and symptoms of 
haemorrhagic diathesis, it is suggested not to use 
antithrombotic drugs; however, the final decision 
should be based on individual assessment of potential 
benefits and disadvantages resulting from antithrom-
botic treatment or its discontinuation.
5. If transfusion of platelet concentrate is impossible or 
contraindicated and if there are significant clinical 
symptoms of haemorrhagic diathesis and acute epi-
sode of DVT of lower extremities could be life-threat-
ening, implantation of a retrievable inferior vena cava 
filter should be considered in order to prevent PE. 
After resolution of contraindications to antithrombotic 
treatment the filter should immediately be removed 
and appropriate doses of antithrombotic drugs should 
be introduced. Literature data show that implantation 
of an inferior vena cava filter could cause poorer long-
term prognosis (e.g. more frequent DVT recurrences) as 
compared to patients with VTE without filter implan-
tation (these data are also relevant to cancer patients) 
[155–157]).
6. In the chronic treatment of cancer patients with con-
comitant thrombocytopaenia and VTE the following 
is suggested:
 a. reduction of LMWHs doses by 50%, if platelet count 
is in the range 25–50 G/l and there are no bleedings; 
 b. cessation of antithrombotic treatment if platelet 
count is < 25 G/l and/or there are significant symp-
toms of haemorrhagic diathesis [2C].
5.5. Treatment of cancer patients with VTE and 
renal insufficiency 
The risk of bleeding complications in patients with renal 
insufficiency resulted from the use of therapeutic doses of 
LMWHs administered s.c. is two-fold higher as compare to 
patients with normal renal function [158]. There is a lack of 
data regarding accumulation of dalteparin. RCTs assessing 
the efficacy and safety of VTE treatment with DOAC in-
cluded only 2.6–10% of cancer patients, and patients with 
eGFR < 50 ml/min accounted for only 7–21% of patients 
analysed in those trials. Elimination of DOAC through the 
kidneys is in the range between 80% (dabigatran) and 25% 
(apixaban); however, for rivaroxaban and edoxaban they 
are 33% and 35%, respectively [159]. The usefulness of 
DOAC in the prevention and treatment of cancer patients 
with VTE and renal insufficiency was not assessed to date 
in RCTs. Guidelines regarding ESC in PE patients allows 
for the use of DOAC in eGFR > 30 ml/min if the bleeding 
risk in cancer patients is not high, which is associated with 
chronic treatment of VTE in patients with good prognosis. 
The majority of experts consider treatment with DOAC in 
cancer patients and renal insufficiency as not indicated 
[8, 104, 153]. Nevertheless, this is possible in carefully 
selected patients.
Renal insufficiency significantly increases the risk of 
VTE recurrence in cancer patients receiving antithrombotic 
drugs. In the CATCH study VTE recurrence during the first six 
months was detected in 14% of patients with eGFR < 60 ml/
min but only 8% in the remaining patients [160].
Guidelines [23, 104, 105, 153, 161, 162]: 
1. In the initial treatment of cancer patients with VTE and 
renal insufficiency it is suggested to use intravenous 
UFH in therapeutic doses for 5–10 days with monitoring 
of APTT, which should be prolonged 1.5–2.5-fold as 
compare to baseline value. VKA could be introduced 
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already on the first day together with UFH withdrawal, 
provided that INR is > 2 for two consecutive days [2C].
2. Treatment with LMWHs with monitoring of anti-Xa ac-
tivity could be an alternative option; however, optimal 
therapeutic concentration of LMWHs in this group of 
patients was not established to date. In patients without 
renal insufficiency treated with LMWHs, anti-Xa activity 
four hours after LMWH injection should account for 
0.6–1.0 IU/ml during administration every 12 hours and 
1.0–1.5 IU/ml during administration every 24 hours. An-
other option for patients treated with therapeutic doses 
of LMWHs and with eGFR < 30 ml/min is reduction of 
standard LMWH dose by 50% [2C].
3. In patients with end-stage renal disease during acute 
phase of VTE extracorporeal haemodialysis could be 
used in order to increase the safety of antithrombotic 
treatment. Indications to this procedure as well as doses 
of LMWH need to be established individually.
4. DOAC can be recommended only in selected cancer 
patients, with eGFR > 15 ml/min (minimal value for 
treatment with apixaban or rivaroxaban according to 
manufacturer’s information), eGFR > 30 ml/min (minimal 
value for treatment with dabigatran), when administra-
tion of nephrotoxic drugs or drugs strongly influencing 
activity of cytochrome P450 (3A4) isoenzyme and P-gly-
coprotein is not planned, with exclusion of patients with 
intracranial tumour or tumour in other locations with 
bleeding risk, and in patients with thrombocytopaenia 
or liver injury [2C].
5. The decision about initiation of antithrombotic treat-
ment in cancer patients with renal insufficiency needs to 
be individually assessed because there is increased risk 
of bleeding complications; however, in life-threatening 
situations, e.g. in patients with PE of high death risk, this 
indication is considered as relative.
6. In order to prevent recurrences it is recommended to 
use LMWHs for 3–6 months, and then VKA or LMWHs 
chronically or until cancer resolution [2C].
5.6. Treatment of pregnant women with 
coincidence of cancer and VTE
In pregnant women with cancer and coincident VTE initial 
treatment is mainly based on LMWHs and UFH, which do not 
cross the placenta. Fondaparinux is not registered for the 
treatment during pregnancy, but during in vitro studies on ex-
perimental models it was indicated that it also does not cross 
the placenta [163]. The duration of VTE initial treatment is 
most commonly 5–7 days, but in selected cases, e.g. extensive 
thrombosis in iliofemoral part, prolongation of therapy up to 
two weeks could be considered (see below). Dosing of LM-
WHs and UFH during initial VTE treatment in pregnant women 
does not differ from treatment of other patient populations. 
In patients with renal insufficiency, in obese women, and in 
case of doubts regarding the efficacy and safety of LMWHs 
during pregnancy, serum anti-Xa activity should be measured 
four hours after last injection of the drug. When injections of 
therapeutic doses of LMWHs are administered every 12 hours 
the therapeutic value of anti-Xa should be within the range 
0.6–1.0 IU/ml, but when injected every 24 hours — 1.0–1.5 IU/
ml [164, 165]. Anti-Xa activity should also be assessed before 
the next dose of LMWH; this is recommended in pregnant 
women with prosthetic heart valve, but could also be helpful 
in suspicion of standard dose failure.
Chronic treatment of pregnant women with cancer and 
after VTE episode should include UFH or LMWHs adminis-
tered until the end of pregnancy and at least six weeks after 
the labour, altogether not shorter than six months. The daily 
dose of LMWHs in those cases should not be lower than 50% 
of the therapeutic dose. Some authors recommend contin-
uation of LMWHs administered in therapeutic doses with 
anti-Xa activity measured every 1–3 months until the end of 
pregnancy. VKA are contraindicated during pregnancy; how-
ever, they could be used after giving birth by breast-feeding 
women as they are not excreted into human milk. 
In order to reduce bleeding risk during delivery the last 
therapeutic dose of LMWH or UFH should be injected no 
later than 24–36 hours before planned induction of labour 
[101, 102]. Infusion of UFH should be finished 4–6 hours be-
fore planned delivery. If labour spontaneously starts during 
the full anticoagulation period central anaesthesia should 
be abandoned. In case of bleeding complications protamine 
sulphate should be used, which shows very high effica-
cy in reverse antithrombotic UFH effect, but significantly 
more weakly inhibits LMWHs. It should be also underlined 
that caesarean section increases the risk of VTE episode by 
two-fold as compare to natural delivery [164, 165]. LMWHs 
should be restarted 12–24 hours after delivery and at least 
12 hours after removal of the catheter for central anaesthe-
sia, provided there are no bleeding complications.
Indications to thrombolytic treatment in pregnant wom-
en are the same as in other patients with acute VTE episode. 
Pregnancy is only a relative contraindication to thrombolysis in 
high-risk PE. Some clinicians consider that thrombolytic drugs 
could lead to placental abruption; however, there are no pub-
lications in scientific literature confirming this opinion [165].
Other methods of treatment of pregnant women with 
cancer and acute VTE episode include venous thrombecto-
my, implantation of an inferior vena cava filter in order to 
prevent PE, and embolectomy of pulmonary artery. Indi-
cations to the mentioned procedures in pregnant women 
do not differ from indications in other groups of patients. 
Guidelines:
1. Treatment of pregnant women with cancer and VTE 
should be conducted according the same rules as in 
other groups of patients [2C].
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2. Both LMWHs and UFH can be used during pregnancy 
[2C]. 
3. VKA use is absolutely contraindicated during the first 
trimester of pregnancy and relatively contraindicated 
and discouraged during the second and third trimesters 
of pregnancy (except in women after implantation of a 
prosthetic heart valve) [2C].
4. Dosing of LMWHs and UFH during initial and chronic 
treatment of pregnant women with cancer and con-
comitant VTE is similar to dosing of those drugs in other 
groups of cancer patients and VTE. Measurement of an-
ti-Xa activity is used for laboratory monitoring of thera-
peutic doses of LMWHs [2C].
5. Fondaparinux is allowed in pregnant women with HITT 
[2C].
6. Dosing of LMWHs and UFH has to be appropriately 
modified during delivery to minimise the risk of bleed-
ing complications.
7. UFH, LMWHs, or VKA could be used during childbed 
(they are not excreted into human milk), but their 
choice is based on the clinical situation (e.g. modality 
of anticancer therapy) and the patient’s preferences 
(influence of treatment on health-related quality of life, 
e.g. resulting from the need for frequent subcutaneous 
injections) [2C].
5.7. Treatment of recurrent VTE during 
antithrombotic treatment
Cancer patients receiving antithrombotic treatment also 
quite often have relapses of VTE [168–171]. However, there 
is lack of strong evidence allowing development of the 
guidelines. Cancer patients with VTE recurrence undergo-
ing optimal antithrombotic treatment should be evaluated 
towards potential progression of malignant disease. In pa-
tients receiving LMWHs or UFH within the last 10–14 days it 
is also important to exclude HITT. Medical history regarding 
the patient’s compliance and rigid taking of antithrombotic 
drugs should also be taken.
Guidelines:
1. In the case of VTE recurrence during treatment with 
LMWHs their dose could be increased by 20–25% IU/ml 
using measurement of maximal anti-Xa activity (1.6–2.0 IU/
ml during administration once daily, 0.8–1.0 IU/ml during 
administration twice daily), or fondaparinux therapy could 
be considered — longer than three months (in case of low 
or moderate bleeding risk) and up to three months when 
bleeding risk is high.
2. In case of VTE recurrence during VKA administration it 
is suggested to replace them with LMWHs or UFH s.c. 
(APTT 1.5–2.5 × control value).
6. Using of antithrombotic treatment in order to 
prolong overall survival in cancer patients
Available evidence from clinical trials does not justify 
use of antithrombotic drugs to prolong survival in cancer 
patients.
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